Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genmab has announced a new Phase 2 clinical study designed to evaluate the efficacy and safety of Rinatabart Sesutecan (Rina-S) in treating non-small cell lung cancer (NSCLC). The study aims to involve up to 240 participants globally and assess Rina-S as a monotherapy treatment option. This research is significant as it focuses on improving outcomes for NSCLC patients, a common and challenging type of lung cancer.
Rina-S, the investigational drug being tested, is administered via intravenous infusion. It is intended to directly target cancer cells and improve patient health, aiming to stabilize or reduce tumor growth over the course of the treatment.
The trial follows a single-group assignment model, with no placebo control, and employs open-label masking. Participants are divided into cohorts with different dosing strategies, making it a flexible and tailored approach to studying the drug’s performance and safety. The primary goal is treatment efficacy for NSCLC.
The study officially begins December 15, 2025, with an estimated average treatment duration of 12 months per participant. This date also marks its first submission and last update to the clinical trial registry. The timeline indicates significant planning and preparation prior to recruitment.
For investors, this update underscores Genmab’s ambition within oncology, particularly in lung cancer treatment—a market poised for growth given high demand for effective therapies. The “not yet recruiting” status may alleviate risks of immediate market pressures but could generate long-term optimism around positive trial results. Investors will likely monitor peer developments in NSCLC treatments such as those from industry giants.
The study remains ongoing with new developments available on the official ClinicalTrials portal.
To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.